Multicellular Tumor Spheroids as a Model for Assessing Delivery of Oligonucleotides in Three Dimensions by Carver, Kyle et al.
Citation: Molecular Therapy—Nucleic Acids (2014) 3, e153; doi:10.1038/mtna.2014.5
© 2014 The American Society of Gene & Cell Therapy All rights reserved 2162-2531/14
www.nature.com/mtna
Introduction
Oligonucleotides can modulate the expression of genes in a 
highly selective manner and thus may provide an important 
approach to therapy for cancer and other diseases where 
current therapeutic modalities lead to unwanted side effects.1 
Delivery of oligonucleotides in vitro is commonly achieved 
through the use of complexation with cationic lipoplexes or 
polyplexes2,3 although other potential delivery strategies have 
also been investigated.4,5 However, the many biological barri-
ers in vivo present a challenge for oligonucleotide delivery to 
their sites of action within cells of interest.6,7
Current nanocarrier delivery systems can passively target 
and accumulate in some tumors through the enhanced per-
meation and retention effect caused by leaky tumor vascula-
ture8 but also tend to diffuse poorly throughout the interstitial 
space of a tumor.9 The result is that drugs localize in regions 
proximal to blood vessels, leaving distal regions of the tumor 
untreated.10,11 Therefore, although oligonucleotide delivery 
systems can concentrate in the tumor, there may not be suf-
ficient penetration and distribution throughout the tissue to 
produce a therapeutic effect.
Even though poor penetration into tumors may be a con-
tributing factor to inadequate therapeutic effects of nanopar-
ticle delivery systems,10 such systems are commonly 
tested in vitro using monolayer cultures where penetration 
is unnecessary. Cells grown in two dimensions lack many 
of the characteristics of those found in tumors, including a 
nutritional gradient, a complex microenvironment, and an 
altered genetic profile.12,13 Furthermore, the nature of ten-
sional forces produced in three dimensions affects how cells 
behave compared with monolayer cultures.14
The multicellular tumor spheroid (MCTS) model compen-
sates for many of the deficiencies seen in monolayer cultures. 
Spheroids on the scale of 200–500 µm develop chemical 
gradients of oxygen, nutrients, and catabolites, while having 
morphological and functional features similar to tumors.15,16 
Therefore, assays utilizing the MCTS model allow for the 
assessment of drug penetration and are more predictive of 
in vivo success compared with monolayer cultures.16,17 There 
is, however, a limited amount of information on delivery and 
effects of oligonucleotides using the MCTS model.
Evaluation of various strategies for oligonucleotide deliv-
ery into tumors in animals is a challenging, expensive, and 
time-consuming process. We suggest that the tumor spher-
oid model may provide a useful, convenient, and rapid 
model for testing and understanding oligonucleotide delivery 
approaches similar to its value for testing conventional anti-
cancer drugs. Here, we examine the behavior of several oli-
gonucleotide delivery approaches in tumor spheroids versus 
conventional tissue culture. In particular, we evaluate molec-
ular-scale arginine-glycine-aspartic acid (RGD)–oligonucle-
otide conjugates versus the same conjugates in nanoscale 
complexes with cationic lipids or polymers. We also examine 




It has been suggested that some studies claiming to utilize 
MCTS were actually performed in nonspheroid loose aggre-
gates,16 which do not establish the proper characteristics 
for testing drug penetration properties.18 Therefore, we first 
characterized the formation of spheroids in our system. His-
tological stains, hematoxylin and eosin (H&E) and  Masson’s 
trichrome, showed that the spheroids grow to ~400 µm 
in diameter and are comprised of very densely packed 
cells; however, they lack substantial collagen deposits 
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Oligonucleotides have shown promise in selectively manipulating gene expression in vitro, but that success has not translated 
to the clinic for cancer therapy. A potential reason for this is that cells behave differently in monolayer than in the three-
dimensional tumor, resulting in limited penetration and distribution of oligonucleotides in the tumor. This may be especially 
true when oligonucleotides are associated with nanocarriers such as lipoplexes and polyplexes, commonly used delivery 
vehicles for oligonucleotides. The multicellular tumor spheroid (MCTS), a three-dimensional model that closely resembles small 
avascular tumors and micrometastases, has been utilized as an intermediate between monolayer culture and in vivo studies 
for the screening of small-molecule drugs. However, spheroids have been little used for the study of various oligonucleotide 
delivery formulations. Here, we have evaluated the uptake and efficacy of splice-switching antisense oligonucleotides using 
various delivery modalities in two- and three-dimensional culture models. We find that the size of the delivery agent dramatically 
influences penetration into the spheroid and thus the biological effect of the oligonucleotides. We hypothesize that the MCTS 
model will prove to be a useful tool in the future development of oligonucleotide delivery formulations.
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(Figure 1a,b). In agreement with previous reports on MCTS 
of this approximate size, a homogenously positive Ki67 stain 
demonstrated that there is no quiescent core of cells. Based 
on these observations, A375 cells form valid spheroids for the 
MCTS model and represent a potentially useful in vitro model 
for early-stage, avascular tumors as well as micrometastasis.
Comparison of monolayer and MCTS uptake
To begin to evaluate the transport properties of spheroids, 
we simply examined the uptake of TAMRA-labeled 623 or its 
RGD conjugate (Figure 2a,b). As seen, the uptake of 623 
or RGD-623 increased progressively with dose with higher 
levels of uptake being attained with the RGD-623 conjugate, 
in agreement with a previous work in monolayer culture.19 For 
the remainder of our studies, we decided to work with the 
RGD-623 conjugate.
One of the reasons that therapeutics screened in mono-
layer cultures have reduced efficacy in vivo is their failure to 
effectively penetrate and distribute throughout the tissue.10 In 
addition, as the size of a delivery formulation increases, pen-
etration through the tumor decreases.20,21 The attenuation of 
penetration may be due to limited intercellular space and cell 
surface area when compared with monolayer culture. To test 
whether the MCTS model can effectively differentiate delivery 
formulations of different sizes, we treated cells grown in both 
monolayer and spheroid conditions and measured cellular 
uptake of a TAMRA fluorophore-conjugated splice-switching 
oligonucleotides (SSOs). Uptake of oligonucleotides via cat-
ionic lipid complexes (mean particle size = 870 nm) or poly-
plexes (polyethylenimine) (mean particle size = 336 nm),22 in 
both A375 and HeLa cells, was substantially higher than free 
oligonucleotides in monolayer culture (Figure 3a,e).
When used in three-dimensional spheroid culture, the larger 
oligonucleotide formulations displayed significantly reduced 
delivery compared with their two-dimensional levels, as well 
as to the uptake of free RGD-623 oligonucleotides (Figure 
3b,f). The profile of the flow cytometry histograms of TAMRA 
fluorescence also shows that the distribution of the complexed 
oligonucleotides was very heterogeneous in spheroids com-
pared with monolayer culture, with values ranging over three 
decades (Figure 3c,d). Interestingly, there was little difference 
in free RGD-623 oligonucleotide uptake between monolayer 
and spheroid cultures, suggesting that the conjugated SSO 
was able to penetrate into the MCTS. The unconjugated SSO, 
623, was also able to diffuse throughout the spheroid (data 
not shown), suggesting that the result is more due to the size 
of the oligonucleotides rather than specific binding via RGD. 
We also examined the effect of serum on the uptake process. 
As seen in Supplementary Figure S1, the inclusion of 10% 
serum produced only a very modest reduction in uptake of the 
RGD-623 conjugate by the spheroids.
Because uptake of oligonucleotides initially leads to 
sequestration within endosomal compartments, we chose to 
also test the small-molecule Retro-1, which we have previ-
ously shown to improve oligonucleotide release from endo-
somes in monolayer culture.23 To confirm that Retro-1 works 
on endosome stability rather than uptake, we examined its 
effects on the accumulation of oligonucleotides. Retro-1 had 
no effect on uptake of RGD-623 in either monolayer or MCTS 
cultures (Figure 3).
To further assess the uptake and distribution of the various 
delivery formulations in MCTS, we imaged spheroids using 
confocal microscopy (Figure 4a). At a penetration depth 
of 70 µm, the limit of the laser, the cationic lipid or polymer 
complexed oligonucleotides were only able to accumulate in 
Figure 1  Characterization of spheroid morphology. Spheroids 
generated from (a) A375 GFP654 and (b) A375 Luc705 cell lines 
were fixed and sectioned prior to being stained with hematoxylin 
and eosin (H&E), Masson’s trichrome (MTC), or Ki67. Bar = 200 µm. 
GFP, green fluorescent protein. 
H&E
200 µm 200 µm 200 µm




Figure 2 Cellular uptake of unmodified 623 and RGD-623. (a) 
A375 GFP654 and (b) A375 Luc705 spheroids were treated with 
various doses either unmodified 623-TAMRA or RGD-623-TAMRA 
splice-switching oligonucleotide for 16 hours. After dispersion of the 
spheroids, TAMRA fluorescence was measured by flow cytometry 
and quantified as cellular uptake as mean ± SEM. n = 3. GFP, green 
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cells at the exterior of the spheroid as depicted by the ring 
of fluorescence. Uptake of the free oligonucleotides, on the 
other hand, was variable from cell-to-cell but was distributed 
throughout the spheroid. Differences between the delivery for-
mulations observed by confocal microscopy were confirmed 
by physically sectioning the spheroids and imaging TAMRA 
fluoresence (Figure 4b) at a section ~80-µm deep and using 
a 4′,6-diamidino-2-phenylindol counterstain to demonstrate 
the cell density of spheroids at the given depth (Figure 4c).
Comparison of splice-switching efficacy
We further sought to assess how oligonucleotide effi-
cacy differs between two- and three-dimensional cell cul-
tures. Cationic delivery formulations not only enhance the 
uptake of oligonucleotides in monolayer cultures but also 
improve delivery to the site of action within the cell. Oligo-
nucleotides entering the cell via free uptake mechanisms 
remain sequestered within endosomes, resulting in a lim-
ited biological effect.24 As expected, the cationic complexes 
significantly increased the induction of splice correction 
of both the green fluorescent protein 654 (GFP654) and 
Luc705 reporter genes in cells grown in monolayer culture, 
whereas free oligonucleotide induction levels were only 
slightly higher than untreated controls (Figure 5a,c). The 
addition of Retro-1 to free uptake samples resulted in a sig-
nificant increase in splice correction as we have reported 
previously.23 A RGD-623 mismatch oligonucleotide was 
used in GFP654 cells to eliminate the possibility that the 
delivery formulations were having a direct effect on splice 
switching.
Figure 3 Differential cellular uptake in two- and three-dimensional culture. A375 GFP654 cells grown in (a) monolayer or (b) spheroid culture 
were treated with 100 nmol/l in the specified delivery formulation for 16 hours. Cellular uptake was quantified as TAMRA fluorescence measured by 
flow cytometry as mean ± SEM. n = 3–10. (c,d) Representative flow cytometry histograms of monolayer and spheroid uptake, respectively. Red, 
control; blue, RGD-623; green, RGD-623 L2K; teal, RGD-623 polyethylenimine (PEI). HeLa Luc705 cells grown in (e) monolayer or (f) spheroid 
were treated with 100 nmol/l of the specified delivery formulation of the RGD-623-TAMRA for 16 hours. Cellular uptake was quantified as TAMRA 
fluorescence normalized to protein content measured on a FLUOstar Omega plate reader as mean ± SEM. n = 3–7. In some cases, Retro-1 was 
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In MCTS, cationic lipid and polyplex oligonucleotide com-
plexes displayed significantly reduced splice switching com-
pared with their effects in monolayer culture (Figure 5b,d). 
This result is most likely due to the limited penetration of 
the complexed oligonucleotides in spheroids. Furthermore, 
the lipoplexes exhibit a negative zeta potential, whereas the 
polyplex charge is positive,22 suggesting that any reduction 
in penetration is most likely due to the size of the complex 
rather than charge effects. In A375 GFP654 spheroids, 
the greater penetration and distribution of free RGD-623 
throughout the spheroid seems to compensate for the poor 
release from endosomes, resulting in equivalent induction 
compared with complexed oligonucleotides across all doses 
investigated (Figure 6a,b). Enhancing the endosomal 
release of RGD-623, through incubation with Retro-1, signif-
icantly improved the induction seen in both spheroid types. 
In HeLa Luc705 cells, induction through Lipofectamine 
2000 was still greater than free RGD-623 most likely due to 
the fact that luciferase measures total induction instead of 
a percentage of affected cells (Figure 5). Therefore, large 
induction at the periphery of the spheroid most likely drove 
up the overall induction measured. Regardless, there is a 
remarkable attenuation of induction between monolayer and 
spheroid cultures for the cationic complexes that is similar 
for both cell lines.
Figure 4 Comparison of delivery formulation penetration 
in spheroids. Spheroids were treated with 100 nmol/l of the 
oligonucleotides using the specified delivery method (free, lipoplex 
(L2K), or polyplex (polyethylenimine (PEI))) for 16 hours and then 
fixed and (a) mounted for confocal microscopy or (b) sectioned for 
wide field fluorescence microscopy. (c) 4′,6-diamidino-2-phenylindol 
fluorescence depicting the density of cells within the section 
spheroids. Confocal image is at a depth of 70 µm, wide field section is 
at a depth of ~80 µm. Bar = 200 µm. GFP, green fluorescent protein.
Free
200 µm 200 µm 200 µm
200 µm200 µm200 µm





Figure 5 Differential efficacy of delivery formulations in monolayer and spheroid culture. A375 GFP654 cells were treated in (a) 
monolayer and (b) spheroid culture with 100 nmol/l of the oligonucleotides using the specified delivery method for 16 hours and further 
incubated for 48 hours. Cells were then fixed and GFP expression was measured using flow cytometry. Quantification is expressed as a percent 
of GFP-positive cells after normalization to control, depicted as mean ± SEM. n = 5–10. HeLa Luc705 cells were treated in (c) monolayer and 
(d) spheroid culture with 100 nmol/l of the oligonucleotides using the specified formulation for 16 hours and further incubated for 48 hours. Cells 
were lysed, and luciferase activity was measured on a FLUOstar Omega plate reader. Quantification is expressed as relative luminescence 
units per µg protein after normalization to control, depicted as mean ± SEM. n = 3–5. HSA, human serum albumin; GFP, green fluorescent 










































































































































































































































































































The use of Lipofectamine 2000 and jetPEI complexes dem-
onstrate how delivery differs between two- and three-dimen-
sional cultures. However, these complexes are larger than 
many delivery vehicles currently under investigation. In order 
to further evaluate the MCTS model, we also assessed the 
delivery of an intermediate-sized delivery moiety. This is com-
prised of RGD-623 oligonucleotides conjugated to human 
serum albumin (HSA), as recently developed in our labora-
tory.25 These small conjugates are ~13 nm in size and there-
fore represent a size at the lower range of nanoparticles.
Interestingly, as seen in Figure 7a,b, there is no significant 
difference in cellular uptake between monolayer and spher-
oid culture. In fact, examination of the flow cytometry histo-
grams shows that there is a unimodal peak of similar mean 
value and distribution pattern in both culture conditions, 
which suggests that the HSA–RGD-623 conjugate is able to 
penetrate and diffuse throughout the spheroid (Figure 7c,d). 
These observations were confirmed with confocal micros-
copy (Figure 7e). Furthermore, when we tested the efficacy 
of the HSA–RGD-623 conjugate in GFP654 cells, there was 
no loss of splice-switching induction between monolayer and 
spheroid culture (Figure 8). Confocal microscopy of a HSA–
RGD-623– and Retro-1–treated spheroid demonstrates that 
the induction of GFP was not simply on the periphery.
Taken together, these data suggest that the MCTS model 
is able to differentiate between various oligonucleotide 
delivery formulations. The large complexes fail to penetrate 
through the spheroids, whereas the smaller conjugates are 
able to effectively diffuse through the interstitial space of the 
spheroids. Conjugation of RGD peptides to the 623 oligonu-
cleotides enhanced cellular uptake without leading to a bind-
ing site barrier effect. MCTS, therefore, may provide a useful 
intermediate step that can screen oligonucleotide delivery 
methods before proceeding to in vivo experiments.
Discussion
Oligonucleotides can modulate gene expression in tumor 
cells in monolayer cultures. However, in order to elicit these 
effects, a delivery system such as cationic lipoplexes or 
polyplexes is usually required. The unique nature of the 
tumor microenvironment, including densely packed cells, 
poses additional biological barriers that are challenges for 
oligonucleotide delivery.26 Therefore, the development of 
next-generation delivery modalities must be tested against 
these barriers. Although xenograft tumors have been shown 
to effectively mimic clinical responses to drugs,27,28 the high 
animal burden, cost, and difficulty in performing xenograft 
models limit their use to late-stage oligonucleotide delivery 
candidates. Therefore, an in vitro culture system that more 
accurately models tumors than monolayer cultures would be 
beneficial and cost effective for early-stage and high-through-
put screening of oligonucleotide delivery formulations.
The MCTS is one of the most widely characterized three-
dimensional culture systems and has been shown to resem-
ble small avascular tumors and micrometastasis.17 Much 
interest has been directed at MCTS for the screening of 
small-molecule drugs,12,26,29,30 and the model has been shown 
to mimic in vivo drug efficacy.31,32 However, there are limited 
data on the usefulness of spheroids for the assessment of 
oligonucleotide delivery formulations.33
In this study, we aimed to evaluate the utility of the MCTS 
model for testing oligonucleotide delivery strategies. Because 
cationic lipoplexes and polyplexes are the most widely used 
delivery methods in monolayer cultures, we initially tested 
their efficacy in spheroids. It is well known that while nanocar-
riers tend to concentrate in tumors due to enhanced perme-
ation and retention effect, they sometimes fail to adequately 
penetrate through the tumor interstitial space.11 As would be 
expected due to their large size, we demonstrate that the 
delivery of oligonucleotides with the Lipofectamine 2000 lipo-
plex and jetPEI polyplex formulations is significantly attenu-
ated in MCTS when compared with monolayer cultures. The 
large complexes can only deliver their payloads to the exte-
rior cells of the spheroid, limiting both the percentage of cells 
induced (GFP654) and total induction (Luc705) compared 
with that in monolayer cultures.
Compared with complexed oligonucleotides, uptake of 
“free” RGD-623 in two dimensions is small as is the overall 
induction of splice switching. The limited induction results 
from both a lower total uptake of oligonucleotides and 
entrapment within the endosomal compartments of the cell. 
As we have shown previously, the small-molecule Retro-1 is 
able to significantly enhance the induction efficacy of SSOs 
by promoting release from endosomes.23 Interestingly, the 
Figure 6 Dose response in monolayer and spheroid cultures. 
A375 GFP654 cells were treated by varying doses of oligonucleotide 
formulations in (a) monolayer and (b) spheroid cultures as 
mentioned in Figure 5. Depicted as mean ± SEM. n = 3–6. HSA, 
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uptake and induction profile of free oligonucleotides as 
well as the enhancement by Retro-1 was similar between 
monolayer culture and spheroids. These results suggest 
that molecular-scale RGD–oligonucleotide conjugates are 
not affected by the more complex nature of the spheroid. 
Although we did not test this directly, we anticipate that 
other types of oligonucleotides such as small interfering 
RNA or micro RNA antagomirs that are in the same size 
range as our SSOs would behave similarly in the spheroid 
context.
To further test the discrimination of delivery methods 
in two- and three-dimensional culture, we utilized a small 
(13 nm) nanoconjugate, developed in our laboratory,25 of HSA 
containing, on average, 10 RGD-623 phosphorodiamidate 
morpholino oligonucleotides. The ultra-nanoscale conjugate 
was able to penetrate homogenously throughout the tumor 
spheroid, as demonstrated by the unimodal peak of the flow 
cytometry histogram, and uptake levels were equivalent to 
those seen in monolayer. Furthermore, the splice-switching 
induction profile showed that a similar percentage of cells 
were induced in two- and three-dimensional culture.
Our studies suggest that MCTSs show a strong size dis-
crimination for oligonucleotide carriers. To the extent that 
tumor spheroids accurately represent the behavior of tumors 
in vivo, our data suggest that small multivalent nanoconju-
gates of macromolecular scale may be most effective in 
delivering oligonucleotides to the interior of small avascular 
tumors or in directing therapy to micrometastases. However, 
a follow-up study investigating the efficacy of these various 
delivery formulations in xenograft or orthotopic tumors is nec-
essary to fully validate the utility of MCTSs in this area.
Materials and methods
Cell culture. A375 human melanoma cells were stably trans-
fected with firefly luciferase (A375 Luc705)19 or GFP (A375 
GFP654)22 expression cassettes containing a mutated intron. 
Figure 7 Cellular uptake of human serum albumin (HSA)–PMO conjugates. A375 GFP654 cells grown in (a) monolayer or (b) spheroid 
culture were treated with 100 nmol/l HSA–PMO conjugate with and without conjugated RGD peptides for 16 hours. In some cases, Retro-1 
was added at 100 µmol/l for 2 hours. Cellular uptake was measured as Alexa633 fluorescence by flow cytometry and normalized to control, 
depicted as mean ± SEM. n = 5–10. Representative flow cytometry histograms of treatment with 100 nmol/l HSA–RGD conjugates in (c) 
monolayer and (d) spheroid culture. (e) Confocal image of HSA–RGD-623 conjugate in multicellular tumor spheroid. GFP, green fluorescent 
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HeLa human cervical cancer cells (HeLa Luc705) were stably 
transfected with the firefly luciferase cassette.34 The mutated 
introns can be removed by using an SSO to alter splicing, 
thus giving inducible expression of the reporter, as described 
previously.35 All cells were grown in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma, St. Louis, MO) 
supplemented with 10% fetal bovine serum (FBS).
Generation of MCTSs. A375 GFP654, A375 Luc705, and 
HeLa Luc705 MCTSs were generated using the hanging 
drop method.36 Briefly, cells were trypsinized and resus-
pended in 20% FBS high-glucose DMEM at a concentra-
tion to achieve 8,000 cells per 30 µl (A375 GFP654) or 
2,500 cells per 30 µl (A375 Luc705 and HeLa Luc705). In a 
72-microwell plate (Nunc 438733; Thermo Fisher Scientific, 
Waltham, MA), 30 µl of culture medium with cells was added 
to each well; plates were then inverted and incubated at 37 
°C for 3–5 days on an orbital shaker. Once formed, MCTSs, 
10 spheroids per well, were transferred to a 48-well plate 
coated with 1.5% agarose for treatment.
Formulation and cell treatment. The SSO623 (5′-GTTATTCTT-
TAGAATGGTGC-3′), which can correct the mutated introns 
in GFP654 and Luc705 constructs and induce reporter gene 
expression, or its mismatch control, were used in all experi-
ments.19 Complexes of oligonucleotides with a cationic lipid 
(Lipofectamine 2000; Life Technologies, Grand Island, NY) 
or cationic polymer (jetPEI; Polyplus, Illkirch, France) were 
prepared per the vendor’s instructions. Conjugation of RGD 
(Arg-Gly-Asp) peptide to SSO623 phosphorothioate to form 
RGD-623,19 or SSO623 morpholino (phosphorodiamidate 
morpholino) to RGD and then to HSA (HSA-RGD-623),25 
were performed as described previously. In both monolayer 
and MCTS, “free” oligonucleotide, HSA conjugate, and poly-
ethylenimine polyplex uptake was performed in OptiMEM 
(Gibco, Life Technologies) media, whereas Lipofectamine 
2000 uptake was done in 10% FBS DMEM to limit cellular 
toxicity. All groups were treated for 16 hours. In some cases, 
Retro-1, a small molecule that has been shown to enhance 
release of oligonucleotides from endosome compartments, 
was directly added to the wells at the end of the treatment 
period as previously described.23 Cells were further incu-
bated for 2 hours before being washed and were incubated 
for an additional 48 hours in their native growth media (10% 
FBS DMEM for monolayer and 20% FBS DMEM for MCTS) 
before being harvested for analysis.
Luciferase assay. Cells were washed with phosphate-buff-
ered saline before being digested with luciferase lysis buf-
fer (New England Biolabs, Ipswich, MA) at a dilution of 1:4. 
After centrifugation, 50 µl of luciferin substrate (Promega, 
Madison, WI) was added to 10 µl of lysate, and luciferase 
activity was measured in a plate reader (FLUOstar Omega; 
BMG Labtech, Cary, NC) over a 5-second window. The sum 
of blank corrected data over seconds 2–5 of the window was 
used to quantitate induction. Induction was normalized to 
protein concentration measured with a bovine serum albumin 
assay (Thermo Scientific).
Flow cytometry. Cells were trypsinized and fixed in single cell 
suspension with 4% paraformaldehyde before being resus-
pended in phosphate-buffered saline for flow cytometry on 
an LSR II using a 488-nm laser with 510/20 band pass filter 
(GFP), 561-nm laser with 610/20 band pass (TAMRA), and 
639-nm laser with 675/20 band pass (Alexa 633). After gat-
ing for live singlet cells, uptake was quantified by normalizing 
mean TAMRA fluorescence value with the control cell’s auto-
fluorescence. GFP654 induction was quantified by gating for 
cells expressing a positive level of fluorescence based on 
untreated cells and then normalizing to control levels.
Histology. MCTSs were harvested and fixed in 4% para-
formaldehyde before being cryoprotected in 30% sucrose / 
phosphate-buffered saline. Up to 10 spheroids were placed in 
Figure 8 Induction of GFP by human serum albumin (HSA)–
PMO conjugates. A375 GFP654 cells grown in (a) monolayer or (b) 
spheroid culture were treated with 100 nmol/l HSA–PMO conjugate 
with and without conjugated RGD peptides for 16 hours followed by 
further 48-hour incubation. In some cases, Retro-1 was added at 
100 µmol/l for 2 hours. Cells were fixed, and GFP expression was 
measured using flow cytometry and quantified as a percentage of 
induced cells after normalization to control, depicted as mean ± 
SEM. n = 3–10. Inset: confocal image of representative spheroid 
treated with HSA–RGD-623 and Retro-1. Bar = 200 µm. GFP, green 
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a 1.5% agarose block in order to maintain orientation before 
being embedded in optimal cutting temperature compound 
(Sakura, Torrance, CA) and sectioned. Serial slides were 
then processed with hematoxylin and eosin to demonstrate 
the structure and cell density of MCTS, Masson’s trichrome 
to demonstrate cell density and collagen content within the 
MCTS, a Ki67 antibody (Vector Laboratories, Burlingame, 
CA) to show cellular proliferation throughout the MCTS, or 
mounted with 4′,6-diamidino-2-phenylindol for fluorescent 
imaging. An Olympus IX71 microscope with 10× objective 
and cellsans entry software was used to collect images of the 
spheroid sections. Scale bars, 200 µm, were inserted using a 
micrometer and Fiji software.
Confocal microscopy. Spheroids were harvested and fixed in 
4% paraformaldehyde. After a well was assembled on each 
slide to prevent spheroid morphology from being altered by 
the coverslip, spheroids were mounted on a slide with fluo-
romount G (Electron Microscopy Sciences, Hatfield, PA). An 
Olympus FV1000 confocal microscope with 488-, 559-, and 
633-nm lasers was used to collect Z stack images of spher-
oids starting at the apex of the spheroid, proceeding every 
10 µm until laser penetration faltered (~70 µm in depth). All 
images were taken using a 20× objective.
Supplementary material
Figure S1. Effect of serum.
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